KYNTHEUM

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Netherlands, Poland, Spain, UK.

Active ingredients

The drug KYNTHEUM contains one active pharmaceutical ingredient (API):

1	Brodalumab UNII 6ZA31Y954Z - BRODALUMAB
	Brodalumab is a recombinant fully human monoclonal immunoglobulin IgG2 antibody that binds with high affinity to human IL-17RA and blocks the biological activities of the pro-inflammatory cytokines IL-17A, IL-17F, IL-17A/F heterodimer and IL-25, resulting in inhibition of the inflammation and clinical symptoms associated with psoriasis.
	Read more about Brodalumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
KYNTHEUM Solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AC12		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AC Interleukin inhibitors
Discover more medicines within L04AC12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1750205, 1777956
ES	Centro de información online de medicamentos de la AEMPS	1161155001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	568224
FR	Base de données publique des médicaments	65620419
GB	Medicines & Healthcare Products Regulatory Agency	346264
IE	Health Products Regulatory Authority	88881
IT	Agenzia del Farmaco	045484019, 045484021
LT	Valstybinė vaistų kontrolės tarnyba	1083403, 1084580
NL	Z-Index G-Standaard, PRK	146757
PL	Rejestru Produktów Leczniczych	100417955